Alfresa Holdings (2784) FY2026 Q3 Earnings Report

Quick View

Executive Summary

Revenue increased, while operating income and ordinary income declined. The increase in net income was primarily attributable to a temporary factor, namely gains on the sale of investment securities. Revenue was ¥23,630.9B (+4.5% year on year), operating income was ¥297.3B (down 4.5%), and ordinary income was ¥316.4B (down 4.6%). Meanwhile, net income rose sharply to ¥320.9B (+25.8%), but this included extraordinary income of ¥164.8B, comprising ¥164.7B in gains on the sale of investment securities. Profitability in the core business weakened due to a decline in the gross profit margin.

Factors Affecting Performance

【Revenue】Revenue was ¥23,630.9B (+4.5% year on year), driven by the core Wholesale Business for Prescription Pharmaceuticals and Related Products (89.0% of total revenue, revenue of ¥21,182.2B, +4.9% year on year). The Self-Medication Wholesale Business recorded a modest increase in revenue to ¥2,043.4B (+1.0%), while the Manufacturing Business generated revenue of ¥394.9B and showed a trend toward a real-term decline from the same period of the previous year. Growth remains concentrated in the wholesale businesses.

【Profit and Loss】The gross profit margin declined by approximately 19bp from 7.19% in the same period of the previous year to 7.00%. Although selling, general and administrative expenses increased by 2.9% year on year, below the 4.5% revenue growth rate, this was insufficient to offset the decline in the gross profit margin, and operating income declined to ¥297.3B (down 4.5%). Ordinary income also declined to ¥316.4B (down 4.6%), reflecting a slowdown in the core business. In contrast, net income increased to ¥320.9B (+25.8%), primarily due to ¥164.7B in gains on the sale of investment securities. The ¥156.6B difference between profit before tax of ¥473.0B and ordinary income of ¥316.4B is almost entirely explained by these gains, resulting in a structure of higher revenue but lower core-business profit, alongside an apparent increase in net income driven by extraordinary income.

Segment Analysis

The Wholesale Business for Prescription Pharmaceuticals and Related Products generated revenue of ¥2,118.2B (89.0% of total revenue) and operating income of ¥270.8B (1.3% margin), accounting for the majority of consolidated profit. The Self-Medication Wholesale Business generated revenue of ¥204.3B and operating income of ¥27.4B (1.3% margin). The Manufacturing Business for Pharmaceuticals and Related Products generated revenue of ¥39.5B and operating income of ¥8.9B (2.3% margin), which is relatively high, although it is on a declining-profit trend compared with the same period of the previous year. The core wholesale business's operating income growth rate (+1.1% year on year) was below its revenue growth rate (+4.9%), indicating weak conversion of revenue growth into profit.

Key Financial Indicators

【Profitability】The operating margin was 1.3%, and the net profit margin was 1.4% (1.14% in the same period of the previous year). The gross profit margin was 7.0%, down approximately 19bp from 7.19% in the same period of the previous year, indicating thin core-business margins. 【Cash Flow Quality】The ¥156.6B gap between profit before tax and ordinary income is almost entirely explained by ¥164.7B in gains on the sale of investment securities, indicating that the quality of the increase in net income depends on a temporary factor. 【Investment Efficiency】Annualized ROE was 8.6%, consisting of a 1.4% net profit margin × approximately 1.94x total asset turnover × approximately 3.27x financial leverage. High asset turnover and leverage are compensating for the low margin. 【Financial Soundness】The equity ratio was 30.6% (down from 33.5% in the previous year), the current ratio was approximately 120%, and interest-bearing debt was limited to ¥10.0B in long-term borrowings and ¥20.0B in bonds. The earnings cushion relative to ¥0.26B in interest expense is substantial.

Cash Flow Analysis

As the data does not include a statement of cash flows, funding trends are analyzed based on changes in the balance sheet. Cash and deposits increased 17.3% year on year to ¥2,078.0B, while accounts receivable increased 16.0% to ¥7,494.6B and accounts payable increased 21.9% to ¥11,980.0B. These working capital items expanded at rates significantly exceeding the 4.5% revenue growth rate. Inventories also increased 17.2% to ¥1,843.3B, and it should be noted that the increase in cash balances was accompanied by an expansion in overall working capital. Accounts payable increased at a faster pace than accounts receivable and inventories, suggesting that funding is partly supported by the expansion of trade payables.

Earnings Quality

The 25.8% year-on-year increase in net income to ¥320.9B was largely attributable to extraordinary income of ¥164.8B, mainly consisting of ¥164.7B in gains on the sale of investment securities. Operating income and ordinary income, both of which indicate recurring earning power, declined. Non-operating income was ¥27.1B, including ¥14.9B in dividend income, equivalent to only approximately 0.1% of revenue, and its impact on overall profit and loss was limited. Comprehensive income was ¥284.5B, down 6.8% year on year. In contrast to the increase in net income, this was weighed down by a deterioration of ¥34.0B in the valuation difference on other securities. This divergence indicates that the apparent improvement in net income resulted from the realization of unrealized gains on assets, while the pace of comprehensive capital growth actually slowed.

Earnings Forecasts and Guidance

The cumulative Q3 progress rates against the full-year company forecasts of revenue of ¥31,070.0B, operating income of ¥371.0B, and ordinary income of ¥397.0B were 76.1% for revenue, 80.1% for operating income, 79.7% for ordinary income, and 88.8% for net income. Although the net income progress rate substantially exceeded the standard 75%, this was primarily due to the boost from gains on the sale of investment securities. Progress in the core-business indicators, operating income and ordinary income, remained at approximately standard levels. The company forecasts themselves anticipate full-year declines of 2.6% in operating income and 1.9% in ordinary income, indicating that a decline in core-business margins is also expected for the full year.

Shareholder Returns

The Q2 dividend was ¥34.00 per share, and the full-year dividend forecast is ¥68.00, assuming a year-end dividend of ¥34.00. Based on forecast full-year EPS of ¥198.07, the forecast payout ratio is approximately 34.3%, which is within a conservative range relative to the earnings level. As cumulative net income includes temporary gains on the sale of investment securities, the sustainability of the dividend funding base must be assessed based on the subsequent recovery trends in operating income and ordinary income.

Risk Factors

1. Low-margin structure of the core business: The Wholesale Business for Prescription Pharmaceuticals and Related Products accounts for 89.0% of total revenue, but its segment profit margin is only approximately 1.3%. This structure makes profit highly sensitive to drug price revisions, purchasing terms, and fluctuations in logistics and personnel costs.

2. Expansion of working capital: Accounts receivable increased 16.0% year on year and accounts payable increased 21.9%, both substantially exceeding the 4.5% revenue growth rate. If collection periods for accounts receivable lengthen or inventory accumulation progresses, funding flexibility may come under pressure.

3. Risk of fluctuations in securities valuations: The company holds ¥1,089.9B in investment securities, and the valuation difference on other securities deteriorated by ¥34.0B year on year. Changes in market prices may affect net assets and comprehensive income.

Industry Benchmark (For Reference; Company Research)

Industry Benchmark (trading)

Profitability and Returns

The company's profitability is below the industry median and positioned toward the low-margin end even within the wholesale sector.

Growth and Capital Efficiency

The revenue growth rate is slightly below the industry median but remains within the range.

※Source: Company research

Key Points from the Financial Results

1. Revenue has continued to increase for four consecutive periods, but the gross profit margin declined from 7.19% in the same period of the previous year to 7.00%, resulting in declines in both operating income and ordinary income. Protecting core-business margins will be the key focus going forward.

2. The increase in net income (+25.8%) was primarily attributable to extraordinary income from ¥164.7B in gains on the sale of investment securities. It is necessary to distinguish this from the declining trends in operating income and ordinary income, which reflect recurring earning power.

3. Progress rates against the full-year plan were generally standard at 80.1% for operating income and 79.7% for ordinary income. However, the company forecasts themselves assume a full-year decline in profit, and working capital trends, including the 16.0% rate of increase in accounts receivable, will remain areas requiring close monitoring.

Theoretical Stock Price (Reference Value)

Sensitivity: ¥2,561–¥2,711 at a ±1% change in the cost of equity, and ¥2,631–¥2,637 at a change of ±0.1 in ω.

Notes:

• Because net income progress against the full-year forecast (89%) exceeds the standard level (75%), forecast EPS has been adjusted upward within a maximum range of +10% (because companies ahead of progress tend to exceed forecasts; the adjustment may be excessive for businesses with strong seasonality).
• Because forecast ROE is below the cost of equity, the theoretical value is below book value per share.
• Net assets as of the quarter-end are used, resulting in a timing difference from the full-year forecast.
• As net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-07 / This is a mechanically calculated value based solely on publicly disclosed data and is not a forecast of the market price, a recommendation of any specific investment action, or a prediction or guarantee of future stock prices.)

---

This report is an automatically generated earnings analysis document produced by AI based on XBRL earnings summary data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting a professional as necessary.

---End of Report---